Reducing cell line development timelines with stable pool strategies

Monoclonal (mAbs) and bispecific (bsAbs) antibodies have emerged as leading therapeutic formats within the biopharmaceutical market. Central to their production are Chinese hamster ovary (CHO) cells, the preferred expression system due to their rapid growth and ability to produce high yields of recombinant proteins with human-like post-translational modifications. However, developing clonal cell lines is labor-intensive and time-consuming, contributing to extended timelines and high costs.

In this application note, we present two case studies where CHOSOURCE™ and LabChip™ are combined for the rapid generation of high-quality pool material at scales suitable for preclinical studies and accelerating biotherapeutic development by aiding process optimization.

• Case Study 1: Glycan profile correlation between pool and clone material
• Case Study 2: Early assessment of correct assembly of bispecific antibodies 

The CHOSOURCE Platform is available for research, clinical, diagnostic, and commercialization applications, including services, under specific licenses from Revvity.